Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

July 12, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Malaria,Falciparum

Interventions

DRUG

TB31F

transmission-blocking monoclonal antibody TB31F

OTHER

Normal saline

normal saline as control (placebo)

Trial Locations (1)

RECRUITING

Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Sciences Techniques and Technologies of Bamako, Bamako

All Listed Sponsors

collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

Radboud University Medical Center

OTHER